Immuno-informatics and Bioinformatics Analysis of Type II Asparaginasefrom Campylobacter jejuni and Escherichia coli Activity as Anti-Cancer (ALL)

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, that requiresongoing research for more effective treatments. However, the new approach for using L-asparaginase(L-ASNase) which plays a crucial role in ALL therapy by depleting asparagine and glutamine,essential for leukemic cell survival. This study employed molecular docking and immunoinformaticsto investigate the therapeutic potential of type II L-asparaginase from Escherichia coli andCampylobacter jejuni against ALL. Molecular docking simulations revealed strong binding affinitiesbetween the enzymes and their substrates. The tested L-asparaginase (ASPA) showed binding scoresof -4.5 kcal/mol and -4.7 kcal/mol at two test sites, comparable to or better than the standard sites (-4.8 kcal/mol). Similarly, the tested glutaminase (GLU) enzyme demonstrated binding scores of -4.5kcal/mol and -5.3 kcal/mol, matching or exceeding the standard sites (-4.5 kcal/mol and -5.2kcal/mol). Immunogenicity and allergenicity predictions indicated low antigenicity scores for bothtested and standard enzymes, suggesting a favorable safety profile. These findings highlight thepotential of type II L-asparaginases as safe and effective therapeutic alternatives for ALL. More invitro and in vivo investigations.